(19) World Intellectual Property Organization

International Bureau





(43) International Publication Date 20 October 2005 (20.10.2005)

PCT

(10) International Publication Number WO 2005/097135 A2

(51) International Patent Classification⁷: A61K 31/52, C07D 473/16

Joseph [CH/CH]; Steingrubenweg 112, CH-4125 Riehen (CH).

(21) International Application Number:

PCT/EP2005/003521

(74) Agent: MOLAC, Beacrice; Novartis AG, Corporate Intellectual Property, CH-4002 Basel (CH).

(22) International Filing Date: 4 April 2005 (04.04.2005)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

0407723.6 5 April 2004 (05.04.2004) GB

(71) Applicant (for all designated States except AT, US): NO-VARTIS AG [CH/CH]; Lichtstrasse 35, CH-4056 Basel (CH).

(71) Applicant (for AT only): NOVARTIS PHARMA GMBH [AT/AT]; Brunner Strasse 59, A-1230 Vienna (AT).

(72) Inventors; and

(75) Inventors/Applicants (for US only): BAENTELI, Rolf [CH/CH]; Davidsbodenstrasse 64, CH-4056 Basel (CH). CHENE, Patrick [FR/FR]; 24, rue des CarrièreS, F-68100 Mulhouse (FR). COLLINGWOOD, Stephen Paul [GB/GB]; Novartis Horsham Research Centren, Wimblehurst Road, Horsham, West Sussex RH12 5AB (GB). FURET, Pascal [FR/FR]; 24, rue du Riegelsbourg, F-68800 Thann (FR). MEIER, Peter [CH/CH]; Burgfeldermattweg 53, CH-4123 Allschwil (CH). SCHOEPFER,

- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

 without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(**54**) **Title:** USE OF 9H-PURINE-2,6-DIAMINE DERIVATIVES IN THE TREATMENT OF PROLIFERATIVE DISEASES AND NOVEL 9H-PURINE-2,6-DIAMINE DERIVATIVES

(57) Abstract: The invention relates to the use of 9H-purine-2,6-diamine compounds and salts thereof in the treatment of proliferative diseases and for the manufacture of pharmaceutical preparations for the treatment of said diseases, pharmaceutical preparations comprising 9Hpurine-2,6-diamine compounds, novel 9H-purine-2,6-diamine compounds, and a process for the preparation of the novel 9H-purine-2,6-diamine compounds.

